|
|
PRESSE RELEASE
Lyon, June 16 2022
ADOCIA confirms its eligibility for the PEA–PME
6:00 pm CEST Adocia Euronext Paris: FR0011184241 – ADOC, a clinicalstage biopharmaceutical
company focused on the discovery and development of therapeutic solutions for the treatment of
diabetes and other metabolic diseases, confirms its eligibility for the “PEA – PME” stock savings tax
... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
Lyon, June 14th, 2022
Number of shares and voting rights of
ADOCIA as of May 31st, 2022
6pm CEST Pursuant to the provisions of article L. 2338 II of the French « Code de Commerce » and
article 22316 of the French stockmarket authorities Autorité des Marchés Financiers, or “AMF”
charter ADOCIA SA, a French société anonyme corporation, 115, avenue... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
Lyon, May 20th, 2022
ADOCIA Announces its annual Shareholders’
meeting to be held on June 28, 2022 in Paris
6:00pm CEST Adocia Euronext Paris: FR0011184241 – ADOC, a clinicalstage biopharmaceutical company
focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and
other metabolic diseases, announced... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
Lyon, le 20 mai 2022
ADOCIA annonce la tenue de son assemblée
générale annuelle le 28 juin 2022 à Paris
18h00 CEST Adocia Euronext Paris : FR0011184241 – ADOC, société biopharmaceutique au stade clinique
spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du
diabète et... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
Lyon, May 18th, 2022
ADOCIA Reports Financial Results of First Quarter
2022 and Provides Corporate Update
• 19 million euros received for the sale of its building locate in Lyon and the concomitant
signature of a 12year renewable lease
• 25.3 million cash position as of March 31, 2022
• Significant progresses in the partnership with Tonghua... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
Lyon, May 9th, 2022
ADOCIA Announces the First Patient Dosed In the
BioChaperone® Lispro Phase 3 Program with
Partner Tonghua Dongbao
• First Patient was dosed in this large Phase 3 program enrolling 1300 people with type 1 or
type 2 diabetes in 100 clinical research centers across China
• This development milestone triggers the payment of $5... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
Lyon, le 9 mai 2022
ADOCIA annonce le dosage du premier patient
dans le programme de Phase 3 de BioChaperone®
Lispro avec son partenaire Tonghua Dongbao
• Un premier patient a été dosé dans le cadre de ce vaste programme de phase 3 auquel
participent 1300 personnes atteintes de diabète de type 1 ou 2 dans 100 centres de
recherche... Lire le communiqué |
|
| |
|
| |
